Why Iovance Biotherapeutics Shares Are Soaring Today

What happened

Shares of Iovance Biotherapeutics (NASDAQ: IOVA) were soaring 12.5% higher as of 11:27 a.m. EST on Friday. The nice jump came after the biotech announced updated data from a phase 2 clinical study evaluating lifileucel in treating metastatic melanoma. These results, presented at the Society for Immunotherapy of Cancer (SITC) annual meeting, included findings that patients receiving lifileucel in the second cohort of the study experienced an objective response rate (ORR) of 35% and that the median duration of response was not reached after 11.3 months into the study.

So what

You can look at Iovance's latest news in two ways. If you're the kind of person who sees a glass of water as half full, the updated phase 2 results should make you more optimistic than ever about the prospects for lifileucel. The experimental drug is one of two pipeline candidates that Iovance is evaluating in pivotal studies. Anything that could potentially improve the likelihood of eventual FDA approval for either of these drugs is very good for Iovance.

Scientists in a lab.

Image source: Getty Images.

What if you're the kind of person who sees the glass as half empty? You'll probably focus on the fact that the latest results were only preliminary and only for one cohort in the phase 2 study. It's not out of the question at all for a drug to have some promising preliminary results only to stumble later.

In reality, both perspectives are good ones. It makes sense that Iovance shares would jump on today's announcement. The updated results truly are positive. It also makes sense that many investors would remain cautious about banking too heavily on early results for an unproven drug.

Now what

Iovance CEO Maria Fardis said that the company plans to continue enrolling patients in the pivotal cohort of the phase 2 study of lifileucel. She added that data from this cohort should be the basis for Iovance's anticipated FDA filing for approval of the drug late next year.

Investing in biotech stocks, especially clinical-stage biotechs like Iovance, comes with plenty of excitement. But that excitement can sometimes be short-lived. The potential for lifileucel in treating metastatic melanoma is promising, but there's still a long way to go.

10 stocks we like better than Iovance Biotherapeutics, Inc.
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Iovance Biotherapeutics, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks


*Stock Advisor returns as of June 1, 2019


Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos

    The Motley Fool

    Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

    Learn More